Inclusion Criteria:  Patients aged 18 to 75 years old;  Patients diagnosed with symptomatic paroxysmal atrial fibrillation:  At least 1 ECG or rhythm monitoring documented AF episode within 12 months prior to enrollment.  Ineffective or intolerant of at least one antiarrhythmic drug; Able to understand the purpose of the trial, participate in the trial voluntarily with informed consent form signed by the subject him/herself or his or her legal representative, and willing to complete follow-up visits as required under the protocol.  Exclusion Criteria:  AF secondary to electrolyte imbalance, thyroid disease, or reversible cause; Persistent or long-standing persistent AF; Previous surgery or catheter ablation for AF; Participant known to require ablation outside the pulmonary vein or in cavotricuspid isthmus region (such as atrioventricular reentrant tachycardia, atrioventricular nodalreentry tachycardia, atrial tachycardia, atrial flutter, ventricular tachycardia and Wolff-Parkinson-White syndrome); Previous valve repair, replacement or artificial valve implantation; previous atrial septal defect closure, patent foramen ovale closure cardiac intervention or surgery; Previous left atrial appendage closure; Any myocardial infarction (MI), coronary artery bypass grafting (CABG) procedure or percutaneous coronary intervention (PCI) during the 6-month interval preceding the consent date; Any carotid artery stent implantation or endarterectomy within the previous 6 months; Left atrial diameter≥50 mm (anteroposterior); LVEF <40% on admission, or NYHA class III and IV; Presence of implanted ICD, CRT, permanent pacemaker, or any type of implantable device Documented active thrombus in the left atrium or atrial appendage on imaging; Rheumatic heart disease; Uncontrollable high blood pressure; Hypertrophic cardiomyopathy, myocardial thickening was significantly greater than or equal to 15mm; Frequent premature ventricular beats; Documented thromboembolic event (including TIA) within the past 6 months; Presence of intramural thrombus, tumor or other abnormality that precludes vascular access or catheter manipulation; Severe lung disease, pulmonary hypertension, or any lung disease involving abnormal blood gas or severe breathing difficulties; Anticoagulation contraindications, and history of blood clotting or bleeding abnormalities; Patients with acute systemic infection; Serum creatinine is more than twice the upper normal limit, or have a history of kidney dialysis; Women who are pregnant and/or breast feeding or unable to use contraception during the trial; Enrollment in another clinical trial evaluating other devices or drugs during the same period; Life expectancy less than 12 months (such as patients with advanced cancer); Abnormalities or diseases that the investigator considers to be excluded from the study's coverage.